STOCK TITAN

Kura Oncology CEO buys 101,119 shares on November 16

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) President and CEO Troy Edward Wilson reported two direct purchases of common stock: 98,881 shares at a weighted average price of $7.63 per share on November 13, 2026, and 101,119 shares at a weighted average price of $7.42 per share on November 16, 2026. The trades were executed in multiple transactions at $7.47–$7.79 and $7.27–$7.73, respectively. The reported holdings also include 479,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust, with both entries dated November 13, 2026.

Insider WILSON TROY EDWARD
Role President and CEO
Bought 200,000 shs ($1.50M)
Increase in Position 45.9%
Type Security Shares Price Value
Purchase Common Stock F2 101,119 $7.42 $750K
Purchase Common Stock F1 98,881 $7.63 $754K
Holding Common Stock -- -- --
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 635,456 shares (Direct); Common Stock — 479,194 shares (Indirect, by One Fish Two Fish Revocable Trust); Common Stock — 300,000 shares (Indirect, by Lorax Charitable Remainder Unitrust)
Holdings Before and After: Common Stock, 435,456 to 635,456 shares (Direct)
Footnotes (2)
  1. F1. This transaction was executed in multiple trades at prices ranging from $7.47 to $7.79. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. F2. This transaction was executed in multiple trades at prices ranging from $7.27 to $7.73. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Common shares purchased 98,881 shares Direct purchase on November 13, 2026
Weighted average purchase price $7.63 per share Direct purchase of 98,881 shares on November 13, 2026
Common shares purchased 101,119 shares Direct purchase on November 16, 2026
Weighted average purchase price $7.42 per share Direct purchase of 101,119 shares on November 16, 2026
Indirect trust holding 479,194 shares Held by the One Fish Two Fish Revocable Trust; holding entry dated November 13, 2026
Indirect trust holding 300,000 shares Held by the Lorax Charitable Remainder Unitrust; holding entry dated November 13, 2026
weighted average purchase price financial
"The price reported above reflects the weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did CEO Troy Edward Wilson buy, and at what prices?

Troy Edward Wilson reported purchases of 98,881 shares at a weighted average price of $7.63 per share on November 13, 2026, and 101,119 shares at a weighted average price of $7.42 per share on November 16, 2026. The respective trades occurred across price ranges of $7.47–$7.79 and $7.27–$7.73. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WILSON TROY EDWARD

(Last)(First)(Middle)
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026P98,881A$7.63(1)534,337D
Common Stock11/16/2026P101,119A$7.42(2)635,456D
Common Stock479,194Iby One Fish Two Fish Revocable Trust
Common Stock300,000Iby Lorax Charitable Remainder Unitrust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $7.47 to $7.79. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. This transaction was executed in multiple trades at prices ranging from $7.27 to $7.73. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Teresa Bair, Attorney-in-fact for Troy E. Wilson11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading